Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can magnetic pulses ease Schizophrenia's 'Negative' symptoms?

NCT ID NCT04318977

Symptom relief Sponsor: University of Regensburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help reduce negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and reduced emotional expression. Researchers are comparing two types of rTMS (high-frequency and theta burst stimulation) against a placebo in 62 adults aged 18–75 with stable medication. The main goal is to see if these treatments improve scores on a standard symptom scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could offer a new way to reduce negative symptoms of schizophrenia, such as low motivation or social withdrawal.
What could go wrong
This is a small, early-stage study with only 62 participants, so results may not apply widely. The treatment is also not a cure and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Feb 2020

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ICD-10: schizophrenia with primarily negative symptoms * Age: 18-75 years * at least 35 Points at the composite score of the SANS * stabe medication during the last 2 weeks (at the investigator's discretion) * written informed consent (by the patient or guardian) Exclusion Criteria: * clinically relevant unstable concomitant somatic diseases * previous treatment by rTMS * conditions in which TMS may not be applicated, as e.g., cardiac pacemakers or ferromagnetic implants * history of epileptic seizures * current substance or alcohol abuse, or clinically relevant comorbidity (according to M.I.N.I. interview) * unacceptable concomitant medication (benzodiazepines in higher doses, e.g., Lorazepam \> 2 mg/d, Diazepam \> 10 mg/d) * insufficient knowledge of the language of the country of the treatment site * pregnancy and nursing period * current statutory hospitalisation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Negative symptoms with primary psychotic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Negative symptoms with primary psychotic disorder Schizophrenia

Contacts and locations

Locations

  • Brno University Hospital

    Brno, Czechia

  • University Hospital Aachen

    Aachen, Germany

  • University Hospital Ostrava

    Ostrava, Czechia

  • University of Regensburg

    Regensburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.